Spyre Therapeutics lures Abivax exec to be its CMO

US clinical-stage biotech Spyre Therapeutics (Nasdaq: SYRE) says it has appointed of Sheldon Sloanas its chief medical officer (CMO).

Spyre noted that Dr Sloan brings more than 25 years of experience in both large pharmaceutical and small biotech companies with an extensive track record of program leadership in the field of Inflammation and Immunology. This includes more than 15 years in various leadership roles at Johnson & Johnson (NYSE: JNJ), followed by vice president and program lead for estrasimod in ulcerative colitis at Arena Pharmaceuticals and Pfizer (NYSE: PFE), and most recently CMO and program lead for obefazimod in ulcerative colitis at Abivax (Euronext Paris: ABVX).

"Sheldon's distinguished career provides numerous examples of the talent, leadership, and determination required to create and deliver innovative new therapies to patients in need," said Cameron Turtle, chief executive officer of Spyre. "We have an ambitious roadmap ahead of us as we continue our effort to advance each of our programs into the clinic over the next several months and initiate Phase II studies in 2025. We are grateful to have Sheldon on board to scale and lead our medical organization to deliver on these goals," he added.